By Josh White
Date: Monday 24 Jun 2024
(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients with metastatic colorectal cancer (CRC).
The AIM-traded company said the approval was based on the positive results from the phase three 'FRESCO-2'...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news